INTELLIA THERAPEUTICS ($NTLA) posted quarterly earnings results for Q3 2026 on Thursday, November 5th. The company reported earnings of -$0.91 per share, missing estimates of -$0.81 by $0.10. The company also reported revenue of $7,160,000, missing estimates of $10,670,658 by $-3,510,658.
You can see Quiver Quantitative's $NTLA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INTELLIA THERAPEUTICS Insider Trading Activity
INTELLIA THERAPEUTICS insiders have traded $NTLA stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- JOHN M LEONARD (President and CEO) has made 0 purchases and 3 sales selling 31,675 shares for an estimated $394,729.
- EDWARD J III DULAC (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 12,788 shares for an estimated $175,434.
- MICHAEL P DUBE (VP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 4,505 shares for an estimated $67,485.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
INTELLIA THERAPEUTICS Hedge Fund Activity
We have seen 182 institutional investors add shares of INTELLIA THERAPEUTICS stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 4,526,926 shares (+inf%) to their portfolio in Q2 2026, for an estimated $76,595,587
- BLACKROCK, INC. added 3,253,217 shares (+26.8%) to their portfolio in Q2 2026, for an estimated $55,044,431
- FMR LLC added 2,705,812 shares (+130.9%) to their portfolio in Q2 2026, for an estimated $45,782,339
- ARK INVESTMENT MANAGEMENT LLC added 2,366,437 shares (+16.3%) to their portfolio in Q2 2026, for an estimated $40,040,114
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,883,517 shares (+134.8%) to their portfolio in Q2 2026, for an estimated $31,869,107
- RENAISSANCE TECHNOLOGIES LLC added 1,400,004 shares (+inf%) to their portfolio in Q2 2026, for an estimated $23,688,067
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,207,941 shares (+inf%) to their portfolio in Q2 2026, for an estimated $20,438,361
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
INTELLIA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $NTLA recently. We have seen 5 analysts offer price targets for $NTLA in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Whitney Ijem from Canaccord Genuity set a target price of $49.0 on 06/16/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $25.0 on 06/15/2026
- Silvan Turkcan from Citizens set a target price of $30.0 on 06/15/2026
- David Nierengarten from Wedbush set a target price of $12.0 on 06/15/2026
- William Pickering from Bernstein set a target price of $17.0 on 05/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
